Background
Accumulating evidence suggests that many ovarian cancers represent metastases from occult fallopian tube carcinomas or tumors arising within ovarian endometriosis. We hypothesized that small ovarian volumes, as reflected in nonvisualization by transvaginal ultrasound (TVU), would be a marker of lower ovarian cancer risk, whereas enlargement on serial examinations would indicate higher risk.
Methods
To address these hypotheses, we analyzed serial ovarian volume measurements determined by TVU for 29 321 women (102 787 scans) performed in the ovarian cancer screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Cox models were used to compute hazard ratios (HRs) and 95% confidence intervals (CIs) as measures of association between TVU results and ovarian cancer. We assessed whether increasing ovarian volume preceded diagnosis of ovarian cancer in a nested case-control analysis comparing case patients and control patients matched on age, center, and screening year (1:4 ratio). All statistical tests were two-sided.
Results
Visualization of normal-appearing ovaries at the last TVU scan was associated with marginally higher ovarian cancer risk compared with nonvisualization of the ovaries (HR = 1.42, 95% CI = 1.00 to 2.01). Ovarian volume increased statistically significantly in ovarian cancer case patients one to two years before diagnosis (P < .001), but not in matched control patients.
Conclusion
Our analysis of TVU data suggests that increasing ovarian volume is associated with greater ovarian cancer risk, but it is only detectable one to two years before diagnosis. Ovarian cancer accounted for approximately 14 000 fatalities in the United States in 2013 (1) . The five-year survival rate of women with stage I ovarian cancers exceeds 90%; however, more than 70% of women present at later stages, which portends a poor prognosis (1) . Several screening studies using serum CA-125 testing and transvaginal ultrasound (TVU) scanning have been conducted to determine whether these modalities can detect ovarian cancers at an early stage and improve mortality (2) (3) (4) (5) (6) . To date, studies based on simultaneous screening with CA-125 and TVU have not shown a mortality benefit, and results of those using a two-stage algorithm are pending. Furthermore, accumulating evidence indicates that most ovarian cancers do not arise from ovarian surface inclusion cysts as previously supposed, suggesting that ovarian cancer screening has been predicated on an incorrect model of ovarian carcinogenesis.
A better understanding of ovarian carcinogenesis is critical for improving ovarian cancer screening and prevention. Analyses of the pathology in risk-reducing salpingo-oophorectomy (RRSO) surgical specimens performed among high-risk women have found that many high-grade serous carcinomas, the most common lethal histological subtype of ovarian cancer, arise from the fallopian tube rather than from the ovary as previously assumed (7) . Furthermore, a novel animal model of fallopian tube carcinoma suggests that ovarian involvement may precede and potentiate the development of metastatic disease (8) . In addition, data suggest that the ovaries represent an early site of macroscopic stage I/II invasive highgrade serous carcinoma and the predominant site of involvement for other histological subtypes, some of which arise from preexisting endometriosis (9, 10) . However, the pace and interindividual variation with which tumors in the ovary cause organ enlargement is unknown.
Analogous to pathology studies of RRSO specimens, analysis of serial TVUs in ovarian cancer screening trials may provide insights into the early evolution of the disease, which in turn may influence future screening approaches. Specifically, given our revised views of the pathogenesis of ovarian cancer, we hypothesized that progressive ovarian enlargement secondary to fallopian tube metastases or malignant change in endometriosis would be antecedent to diagnosis. Accordingly, we hypothesized that small ovaries, as reflected by TVU nonvisualization, would reflect atrophy and lower ovarian cancer risk, whereas progressively increasing volume would be related to higher risk, even if below usual thresholds of clinical suspicion. In the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening trial, annual ovarian cancer screening was based on a preset threshold of a serum CA-125 concentration of 35 U/mL or a TVU showing an ovarian volume equal to or exceeding 10 cm 3 or a suspicious cyst (2, 11) . Analysis of results from serial TVU scans in PLCO and similar trials has not been performed. Therefore, we analyzed serial TVU data from PLCO to understand patterns of serial ovarian volume preceding the diagnosis of ovarian cancer.
Methods

Study Population
The PLCO trial included 78 216 women aged 55 to 74 years that were enrolled at 10 US clinical centers between 1993 and 2001 (12) . Women were randomly assigned to the screening or usual care arm and followed for up to 13 years or until December 31, 2009 . Women with a history of ovarian cancer were not eligible to participate. Initially, women who had undergone bilateral oophorectomy were ineligible, but this exclusion was removed in 1996. Women without ovaries, comprising 12% of the total women enrolled in PLCO, were not screened for ovarian cancer. These women are not included in this analysis. Of the 32 636 eligible women randomly assigned to screening, we excluded 3315 (10.2%) women without adequate TVUs and CA-125 data. Women gave written informed consent, and protocols were approved by review boards at the National Cancer Institute and individual centers.
At study entry, participants completed a self-administered baseline questionnaire to obtain demographic information, risk factor data, and medical history. Between 2006 and 2008, a supplemental questionnaire was administered to update risk factor information, including oophorectomy status.
Screening
Trained examiners following standard techniques performed TVUs using 5 to 7.5 MHz transvaginal probes at baseline and then repeated this test annually for up to three years. TVUs were considered adequate if the iliac vessels were identified. Over 97% of the tests were considered adequate during a given screening year. Quality assurance TVUs were conducted for a subset of women during every screening year, with over 98% agreement between scans.
Ovaries were considered nonvisualized if not identified after a search of at least five minutes. For visualized ovaries, the longitudinal, transverse, and anteroposterior dimensions were measured and used to estimate ovarian volume by applying the prolated ellipsoid formula (0.523×longitudinal diameter×transverse diameter×anteroposterior diameter) (12, 13) . TVUs were considered abnormal if ovarian volume or cyst volume was greater than 10 cm 3 or if cysts had solid areas, papillary projections, or mixed solid-cystic components were found (12) . The reliability of ovarian volume measurements by TVU has been shown to be high (14, 15) .
Blood samples collected at baseline and for up to five subsequent annual screening examinations were centrally tested for serum CA-125 levels using the Fujirebio CA-125 II radioimmunoassay (Malvern, PA) (16) . CA-125 levels above 35 U/mL were considered abnormal. Women with an abnormal TVU or CA-125 result were referred to their primary care physician for management.
Ovarian Cancer Ascertainment
Incident ovarian cancer cases were ascertained through routine follow-up of abnormal screening test results and through annual study update forms mailed to participants and confirmed by review of medical records, death certificates, and cancer registries. Loss of follow-up was negligible (1.2% of women in our analysis had not responded at the last follow-up as of December 31, 2009 (17) .
Statistical Analysis
Relationships of Ovarian Visualization and Ovarian Volume
With Ovarian Cancer Risk. Ovaries were categorized as visualized if at least one ovary was identified. Ovarian volume for each subject was defined as the larger of the bilateral measurements; when only one ovary was visualized, this value was used.
Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) as measures of association between TVU visualization (nonvisualized, visualized-normal, visualized-abnormal) or ovarian volume and incidence of ovarian cancer, with age serving as the time metric. In analyses relating TVU visualization to ovarian cancer risk, follow-up started at the age of the last TVU and ended at the age at diagnosis of invasive ovarian cancer or censoring. Censoring events were death, bilateral oophorectomy, loss to follow-up, or diagnosis of a borderline ovarian tumor or other ovarian neoplasm. The associations between ovarian volume and risk of ovarian cancer were estimated with follow-up starting at the age of the last volume measurement. CA-125 levels measured within three months of TVU were considered concurrent. Results from minimally adjusted and fully adjusted analyses are presented (see Supplementary Tables 1-3 for assessment of potential confounders; analysis for Supplementary Table 1 is based on Cox models and for Supplementary Table 2-3 on logistic regression, all available online). Ovarian visualization, ovarian volume, and CA-125 levels were also analyzed as time-dependent variables. The proportional hazard assumption was tested based on the slope of the Schoenfeld's residuals (18) , and there were not statistically significant departures from proportionality. Women of all racial/ethnic groups were included in the analysis. The majority of women (89.2%) were of white race and non-Hispanic ethnicity.
Changes of Ovarian Volume Over Time
To assess whether increasing ovarian volume presaged the diagnosis of ovarian cancer, we selected four control patients per case, matched on age (<60/60-64/65-70/≥70 years), calendar year, and screening center, and who had at least one volume measurement. The relationship between increasing ovarian volume and corresponding CA-125 levels was also explored. Linear regression models were fit to (log-transformed) ovarian volume or CA-125 levels by years to diagnosis. Models were adjusted for matching variables and for either log-transformed CA-125 levels or log-transformed ovarian volumes for case patients and control patients combined. The residuals of these regression models were plotted against years to diagnosis/selection. A lowess function (19) was used to estimate the average ovarian volume, CA-125 levels, and the residuals over time separately for case patients and control patients. Changepoint analysis was performed separately for case patients and matched control patients (20) to assess if changes in the mean ovarian volume or CA-125 levels were present and when they occurred in relation to time prior to diagnosis. We excluded measurements within three months of diagnosis/selection to avoid a potential influence of late increases concurrent with diagnosis.
To assess the discriminatory ability of ovarian volume during the prediagnostic period, we computed the area under the receiver operating characteristic (AUC) curve. The AUC of a score that combined ovarian volume and CA-125 was also computed (21) . Ninety-five percent confidence intervals for the AUCs were computed based on the quantiles of the bootstrap empirical distribution, based on 10 000 bootstrap replicates. For the bootstrap, we resampled case patients and control patients separately with replacement.
Analyses were performed using the R software (version 3.0.2). The change-point analysis was done using the changepoint library, and the AUC statistics were computed using the ROCR library. All statistical tests were two-sided, and a P value of less than .05 was considered statistically significant.
results
Relationships of Ovarian Visualization and Ovarian Volume With Ovarian Cancer Risk
Results for 29 321 women undergoing a total of 102 787 TVUs were analyzed (median follow-up time = 12.1 years, interquartile range = 10.5-12.9 years). During follow-up, 192 women were diagnosed with ovarian cancer (Supplementary Table 4 , available online).
Approximately 40% of TVU scans resulted in nonvisualization of ovaries. Annual frequencies declined from 1994 to 2003 (from 64% to 43%, P trend = .001) (Supplementary Figure 1 , available online). This decline was observed after stratifying by age. Among women scanned four times (71.0% of participants), 82.5% had the same visualization results (nonvisualized vs visualized) in at least three out of four TVUs.
Ovarian visualization was statistically significantly inversely associated with older age, increasing body mass index (BMI), younger age at menopause, older age at menarche, higher parity, later age at first birth, and prior gynecological surgery (Supplementary  Table 2 , available online).
Women with visualized-normal ovaries at the last TVU scan had an increased risk of ovarian cancer compared with those with nonvisualized ovaries (HR = 1.42, 95% CI = 1.00 to 2.01, P = .05) ( Table 1) . However, women with visualized-abnormal ovaries were , ovarian volumes between 2 and 10 cm 3 at the last measurement were not associated with ovarian cancer risk (HR = 1.14, 95% CI = 0.67 to 1.94, P = .63) ( Table 1) .
Using longitudinal TVU information, women with visualizednormal TVU results were not at statistically significantly increased ovarian cancer risk compared with women with nonvisualized ovaries at the most recent scan (HR = 1.41, 95% CI = 0.91 to 2.18, P = .13) ( Table 2) ; women with visualized-abnormal TVU results at the most recent scan were at statistically significantly increased ovarian cancer risk (HR = 6.32, 95% CI = 3.62 to 11.06, P < .001). Serial measurements of ovarian volume were associated with a statistically nonsignificant increased risk (HR = 1.43, 95% CI = 0.70 to 2.91 for ovarian volumes between 2 and 10 cm 3 , P = .33) ( Table 2) . Results for serous and nonserous cancers were similar ( Table 3) .
Changes of Ovarian Volume Over Time
Ovarian volumes of case patients and control patients did not differ until two years before diagnosis, when the mean ovarian volumes of the case patients, but not control patients, started to rise ( Figure 1A) . A statistically significant change in the mean volumes of the case patients was detected 1.47 years before diagnosis (P < .001); volumes of control patients did not change ( Figure 1B ). We detected a statistically significant increase in CA-125 concentrations of case patients 1.13 years before diagnosis (P < .001), but not of control patients. Ovarian volumes and CA-125 levels were statistically significantly associated (Supplementary Table 3 , available online), and adjusting each factor for the other attenuated casecontrol differences for both measurements (Figure 1, C and D) .
Following these observations, we explored whether the risk of ovarian cancer in relation to visualization and ovarian volume was restricted to two years after the last TVU (Supplementary Table 6 , available online). The increase in cancer risk found for visualizednormal ovaries compared with nonvisualized ovaries remained over time following the last scan, whereas the association for visualizedabnormal ovaries (reflecting exceeding 10 cm 3 volume or cysts) was restricted to the two years following the TVU scan.
Despite the increase in ovarian volume approximately two years before diagnosis, the discriminatory power of ovarian volume was limited to one year prior to diagnosis (AUC for volume = 0.76, CI = 0.67 to 0.84). Moreover, a score combining ovarian volume and CA-125 levels one year prior to diagnosis performed similarly to CA-125 levels alone (AUC for CA-125 levels alone = 0.89, CI = 0.83 to 0.94; AUC: volume and CA-125 combined = 0.91, CI = 0.86 to 0.96).
Discussion
In our detailed analysis, we observed that ovarian nonvisualization, as assessed with TVU methods in PLCO, occurs frequently and often repeatedly for a given postmenopausal woman. The relationship between visualization and age was similar across BMI strata. Given that nonvisualization is strongly associated with agerelated atrophy, we postulate that the lower ovarian cancer risk among these women is consistent with a hormone-and growth factor<en>deficient systemic milieu. We also found that ovarian enlargement, similar to CA-125 elevations, only appeared a year and a half prior to ovarian cancer diagnosis. Review of serial ovarian volumes among women who later developed cancer revealed that a precipitous increase in volume between consecutive measurements was the most common pattern, consistent with rapid growth within the ovary (data not shown). Similarly, among women with ovarian enlargement secondary to cancer, presentation with clinically advanced disease shortly after the volume increase was the rule. The timing of increases in ovarian volume and CA-125 are consistent with a model of rapid evolution of ovarian cancer, as previously suggested, and question the potential of using these approaches to achieve meaningful early detection (22) (23) (24) . * Updated at every TVU scan. All statistical tests were two-sided and considered significant if P < .05. CI = confidence interval; HR = hazard ratio; TVU = transvaginal ultrasound. † Cox model with age as the time variable. Adjusted for calendar year (continuous); baseline hazard function stratified by screening center. ‡ Cox model with age as the time metric. Ovarian visualization models: adjusted for calendar year (continuous), number of pregnancies (≤1 vs >1), and hysterectomy status; baseline hazard function stratified by screening center. Ovarian volume models: adjusted for use of oral contraceptives, pregnancies, duration of use of hormone therapy (never/≤5 years/>5years), endometriosis, tubal ligation, log-transformed levels of CA-125 corresponding to the most recent measurement of ovarian volume, and calendar year (continuous); baseline hazard function stratified by screening center. § Two-sided Wald test.
ǁ Two-sided likelihood ratio test (two degrees of freedom) comparing a model with and without ovarian visualization by TVU in the model.
In the PLCO trial, approximately 40% of subjects had ovaries that could not be visualized by TVU, similar to other studies of postmenopausal women (25, 26) . A higher frequency of nonvisualization was most strongly associated with older age, higher BMI, and hysterectomy with or without partial oophorectomy, while older age at menopause was associated with TVU visualization. Similar results were reported for UKCTOCS baseline TVU scans (25) , except that infertility was associated with ovarian visualization in the UK study but not in PLCO. In contrast to the PLCO data, the University of Kentucky Ovarian Cancer Screening Project reported that about 15% to 20% of scans resulted in ovarian nonvisualization (4, 27) , a difference likely explained by the Kentucky study including both pre-and postmenopausal women (age range = 25 to 92 years; mean age = 56 years).
In the PLCO trial, ovarian nonvisualization was often consistent within individuals and portended a borderline lower ovarian cancer risk than normal-visualized TVU results. Given that our analysis may have included perimenopausal women with fluctuating ovarian volumes secondary to irregular menstrual cycling, we repeated our analysis, restricting to postmenopausal women, and observed similar results. It is unclear why nonvisualization might be a marker of lower cancer risk, but we suggest that ovarian atrophy secondary to reduced exposure to growth factors or hormones might link ovarian nonvisualization, smaller ovarian volume, and lower cancer risk. Prior analyses have found that ovarian volume is directly related to risk of endometrial, breast, and ovarian cancers and to serum hormone levels among women with endometrial cancer (28, 29) . Understanding factors that influence visualization could affect methods for following young, high-risk women, particularly if salpingectomy with deferred oophorectomy is investigated as a strategy to achieve risk reduction while prolonging ovarian function (30, 31) . Our analysis demonstrates that once a woman has a TVU with ovarian nonvisualization, that result is likely to recur. Results for nonvisualized ovaries should not be equated with visualized normal results in future studies without exploration. Nonetheless, some women with nonvisualized ovaries later developed cancer.
We observed that ovarian volume increased about one to two years before diagnosis of ovarian cancer without similar changes in matched control patients. Neither analyzing ovarian volumes as a continuous measure nor modeling serial measures altered this interpretation. Previous analyses have found similar prediagnostic increases for CA-125 and human epididymis protein 4 (HE4) levels (32) . Our analysis confirms the finding that CA-125 levels increase prior to diagnosis; however, when CA-125 levels are adjusted for ovarian volume or vice versa, the effects are diminished.
Strengths of our study include the availability of serial ovarian volume measurements as assessed by TVU data from the PLCO trial, high quality assessment of covariates and endpoints, and long follow-up. Limitations include the relatively small number of incident ovarian cancers. There also was possibly informative censoring, as in the PLCO trial, 1080 out of 3285 (32.9%) women with false-positive screens had an oophorectomy (2) . If these women were more likely to have developed ovarian cancer had they not undergone surgery, then our analysis may underestimate the value of screening because of informative censoring. Last, mixed solid cystic components reported from TVU can be a source of false-positive results, and therefore could be a limitation in our interpretation. However, the majority of abnormal TVUs were because of enlarged volumes. In summary, our data suggest that the development of most ovarian cancers is characterized by occult development followed by explosive growth. Thus, similar to prior reports among average-risk women, we found that available screening tests such as CA-125 and TVU become abnormal too late in the course of ovarian carcinogenesis to enable curative interventions (33) . Research to develop molecular imaging methods for ovarian screening and improved tests for circulating molecular markers are ongoing (34) . Newer 3D scans could improve TVU performance. However, recognition that high-grade serous carcinomas may disseminate from small primary lesions shortly after inception raises questions about the potential of screening to reduce mortality, unless a precursor of this tumor can be identified (24, 35) . Whether efforts to reduce ovarian cancer mortality focus on early detection or other prevention strategies, developing improved models for identifying high-risk women is critical, given the rarity of the disease, the need to perform surgery to rule out cancer, and the inability to monitor equivocal findings without compromising chances for a cure. Understanding the natural history of ovarian cancer is a first step in developing better approaches to prevention and may help improve models for identifying high-risk women.
references Figure 1 . Last measurement of ovarian volume and corresponding CA-125 levels before diagnosis/reference age. Red and black symbols are the log-transformed ovarian volume for the case patients and matched control patients, respectively. The red and black lines are the lowess to estimate the average log-transformed ovarian volume for the case patients and control patients, respectively. The gray line for the ovarian related plots (A and C) is the log of 10 cm 3 , ie, the log of the threshold used to determine an abnormal ovarian volume. The gray line for the CA-125 related plots (B and D) is the log of 35 U/mL, ie, the log of the threshold used to determine an abnormal CA-125 level.
